World's Best Scientists 2026 revealed!
A. Keith Stewart

A. Keith Stewart

D-Index & Metrics

Medicine

D-Index
104
Citations
40642
World Ranking
7037
National Ranking
3698

Overview

A. Keith Stewart is affiliated with the Mayo Clinic in the United States. Their research primarily focuses on medical and biological sciences, with a specialization in hematology, molecular biology, and oncology. Stewart's work intersects with genetics and cancer research as well, exploring complex mechanisms within these fields.

The core topics of their research include multiple myeloma research and treatments, protein degradation and inhibitors, peptidase inhibition and analysis, ubiquitin and proteasome pathways, cancer genomics and diagnostics, CAR-T cell therapy research, and biosimilars and bioanalytical methods.

Stewart has published extensively in several scientific journals, with frequent contributions to the following venues:

  • Blood
  • Blood Cancer Journal
  • Frontiers in Oncology
  • Molecular Cancer Research
  • Mayo Clinic Proceedings

Stewart's research output includes multiple papers on relevant therapeutic and biological topics. Recent publications include:

  • "CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma" (2020, Blood)
  • "Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity" (2020, Molecular Cancer Research)
  • ""Direct to Drug" screening as a precision medicine tool in multiple myeloma" (2020, Blood Cancer Journal)
  • "Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment" (2022, Frontiers in Oncology)
  • "Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like Cells" (2022, Frontiers in Oncology)

The collaborations of Stewart include frequent partnerships with several researchers contributing to their body of work. Frequent co-authors are:

  • Shaji Kumar
  • P. Leif Bergsagel
  • Cecília Bonolo de Campos
  • Nathalie Meurice
  • Neeraj Sharma

The research conducted by Stewart encompasses investigations into the viability of myeloma cells, proteasome inhibitor sensitivity, precision medicine screening approaches, risk-adapted treatment strategies based on gene expression profiling, and the identification of novel biological pathways relevant to therapy-resistant myeloma cells.

Best Publications

  • Initial genome sequencing and analysis of multiple myeloma

    Michael A. Chapman;Michael S. Lawrence;Jonathan J. Keats;Kristian Cibulskis

  • Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma

    Jonathan J. Keats;Rafael Fonseca;Marta Chesi;Roelandt Schop

  • International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

    R Fonseca;P L Bergsagel;J Drach;J Shaughnessy

  • Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

    Jesus G Berdeja;Deepu Madduri;Saad Z Usmani;Andrzej Jakubowiak

  • Genetics and Cytogenetics of Multiple Myeloma A Workshop Report

    Rafael Fonseca;Bart Barlogie;Regis Bataille;Christian Bastard

  • A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

    David S. Siegel;Thomas Martin;Michael Wang;Ravi Vij

  • Clonal competition with alternating dominance in multiple myeloma

    Jonathan J. Keats;Marta Chesi;Jan B. Egan;Victoria M. Garbitt

  • Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

    Antonio Palumbo;Sara Bringhen;Maria Victoria Mateos;Alessandra Larocca

  • Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

    H Quach;D Ritchie;D Ritchie;A K Stewart;P Neeson

  • Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

    Yuan Xiao Zhu;Esteban Braggio;Chang Xin Shi;Laura A. Bruins

  • Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines

    Shaji K. Kumar;Joseph R. Mikhael;Francis K. Buadi;David Dingli

  • Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

    Shaji Kumar;Ian Flinn;Paul G. Richardson;Parameswaran Hari

  • Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides

    Jan B. Egan;Chang Xin Shi;Waibhav Tembe;Alexis Christoforides

  • Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

    C B Reeder;D E Reece;V Kukreti;C Chen

  • CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma

    Suzanne Trudel;Zhi Hua Li;Zhi Hua Li;Ellen Wei;Ellen Wei;Marion Wiesmann;Marion Wiesmann

  • Genetic aberrations and survival in plasma cell leukemia.

    R E Tiedemann;N Gonzalez-Paz;R A Kyle;R Santana-Davila

  • AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies

    Marta Chesi;Davide F. Robbiani;Michael Sebag;Wee Joo Chng

  • International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation

    Antonio Palumbo;S. Vincent Rajkumar;Jesus F. San Miguel;Alessandra Larocca

  • Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial.

    William F. Clark;A. Keith Stewart;Gail A. Rock;Marion Sternbach

  • Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.

    Joseph R. Mikhael;Steven R. Schuster;Victor H. Jimenez-Zepeda;Nancy Bello

Frequent Co-Authors

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative healthcare careers can be an excellent option for those interested in the medical field but seeking flexible or accelerated pathways. For example, direct msn programs online offer non-nurses with a bachelor’s degree a fast-track to advanced nursing roles, opening doors to higher earnings and greater responsibility.

Entry-level nursing positions are also accessible through adn nursing programs. These programs typically take just two years to complete, often with less competitive admissions than traditional four-year degrees.

Not everyone in the healthcare industry works directly with patients. Careers in health administration are in high demand, and many begin with a certificate from accredited medical billing and coding schools with financial aid. These programs teach essential skills and make it possible to start working sooner, often with flexible online learning options.

Additionally, for those who prefer fewer entrance hurdles, an lpn program without teas test can pave the way to a practical nursing career without comprehensive standardized exam requirements.

Best Scientists Citing A. Keith Stewart

Trending Scientists

Recently Published Articles